Retifanlimab
HCC 24-106
Phase 1 small_molecule active
Quick answer
Retifanlimab for Pancreatic Adenocarcinoma is a Phase 1 program (small_molecule) at ACTUATE THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ACTUATE THERAPEUTICS, INC.
- Indication
- Pancreatic Adenocarcinoma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active